Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV)
This grant funds multidisciplinary research to accelerate cures for Hepatitis B in people living with both HIV and HBV, focusing on disease mechanisms, biomarkers, drug targets, and non-invasive diagnostics.
Funder: National Institutes of Health (NIH)
Due Dates: August 19, 2026 (estimated, forecasted)
Funding Amounts: ~$8,000,000 total program funding | Expected 2 awards | Cooperative Agreement
Summary: Supports multidisciplinary research to accelerate hepatitis B cure in persons living with HIV and HBV, focusing on mechanisms, biomarkers, drug targets, and non-invasive diagnostics.
Key Information: Forecasted opportunity; final details may change.
Description
The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is forecasting a funding opportunity for multidisciplinary research aimed at accelerating a cure for hepatitis B in persons living with both HIV and hepatitis B virus (HBV). This program seeks to:
- Elucidate mechanisms of HBV persistence and pathogenesis in the context of HIV.
- Discover and develop clinically relevant biomarkers.
- Discover or validate host and/or new viral drug targets.
- Develop non-invasive diagnostic tools.
Each award will support an observational cohort paired with a multidisciplinary research team, leveraging samples and data from existing clinical repositories and previous cohort studies. The goal is to drive translational research that can inform future clinical strategies for HBV cure in the context of HIV.
